Kalipso Chalkidou
#101,599
Most Influential Person Now
Public health academic and researcher
Kalipso Chalkidou's AcademicInfluence.com Rankings
Kalipso Chalkidoumedical Degrees
Medical
#2454
World Rank
#2880
Historical Rank
Public Health
#516
World Rank
#533
Historical Rank
Epidemiology
#700
World Rank
#728
Historical Rank
Download Badge
Medical
Kalipso Chalkidou's Degrees
- PhD Public Health University of Oxford
- Masters Epidemiology London School of Hygiene and Tropical Medicine
- Bachelors Biomedical Sciences University of Oxford
Why Is Kalipso Chalkidou Influential?
(Suggest an Edit or Addition)According to Wikipedia, Kalipso Chalkidou is the Head of Health Finance at The Global Fund to Fight AIDS, Tuberculosis and Malaria and a Visiting Professor at Imperial College London. Previously she was Director of Global Health Policy at the Center for Global Development and Professor of Practice in Global Health at Imperial College London. Her research considers how local expertise can inform the allocation of scientific and healthcare resources.
Kalipso Chalkidou's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- About the National Institute for Health and Care Excellence - NICE. (2013) (1893)
- A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers (2009) (767)
- A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. (2009) (751)
- Evidence for overuse of medical services around the world (2017) (562)
- NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4 (2018) (530)
- How to formulate research recommendations (2006) (271)
- The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research (2012) (153)
- Comparative effectiveness research and evidence-based health policy: experience from four countries. (2009) (151)
- NCD Countdown 2030: pathways to achieving Sustainable Development Goal target 3.4 (2020) (126)
- Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. (2014) (124)
- Searching for cost effectiveness thresholds in the NHS. (2009) (109)
- Priority-setting for achieving universal health coverage (2016) (105)
- Priority-Setting in Health: Building Institutions for Smarter Public Spending (2012) (89)
- Priority-setting institutions in health: recommendations from a center for global development working group. (2012) (77)
- Evidence-based decision making: when should we wait for more information? (2008) (75)
- Protocol for the development of guidance for stakeholder engagement in health and healthcare guideline development and implementation (2020) (67)
- Health Technology Assessment capacity development in low- and middle-income countries: Experiences from the international units of HITAP and NICE (2017) (62)
- Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research (2007) (58)
- Expensive cancer drugs: a comparison between the United States and the United Kingdom. (2009) (56)
- Helping poorer countries make locally informed health decisions (2010) (51)
- Reflections on the evolution of health technology assessment in Europe (2012) (50)
- Cost-effective public health guidance: asking questions from the decision-maker's viewpoint. (2008) (43)
- Strengthening health technology assessment systems in the global south: a comparative analysis of the HTA journeys of China, India and South Africa (2018) (43)
- Access with Evidence Development in the UK (2012) (41)
- Comparative effectiveness research priorities: Identifying critical gaps in evidence for clinical and health policy decision making (2009) (41)
- Health technology assessment in universal health coverage (2013) (40)
- Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK (2021) (39)
- Implementing pro-poor universal health coverage. (2016) (39)
- Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development (2015) (38)
- Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research (2009) (36)
- Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy (2014) (35)
- Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence. (2009) (35)
- Evidence-informed capacity building for setting health priorities in low- and middle-income countries: A framework and recommendations for further research (2017) (33)
- Social values and health policy: a new international research programme. (2012) (32)
- Engaging the public in healthcare decision-making: quantifying preferences for healthcare through citizens’ juries (2014) (31)
- How can we evaluate the cost-effectiveness of health system strengthening? A typology and illustrations (2019) (30)
- Evidence and values: paying for end-of-life drugs in the British NHS (2012) (29)
- What next after GDP-based cost-effectiveness thresholds? (2020) (28)
- Distributional Cost-Effectiveness Analysis Comes of Age (2020) (28)
- Mapping Priority Setting in Health in 17 Countries Across Asia, Latin America, and sub-Saharan Africa (2016) (27)
- The International Right to Health: What Does It Mean in Legal Practice and How Can It Affect Priority Setting for Universal Health Coverage? (2016) (27)
- Effect of a Quality of Care Improvement Initiative in Patients With Acute Coronary Syndrome in Resource-Constrained Hospitals in China: A Randomized Clinical Trial. (2019) (27)
- Improving health system quality in low- and middle-income countries that are expanding health coverage: a framework for insurance. (2013) (26)
- Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania. (2013) (24)
- Developing institutions for cancer care in low-income and middle-income countries: from cancer units to comprehensive cancer centres. (2018) (24)
- Spending on medical care: more is better? (2008) (24)
- Lockdown is not egalitarian: the costs fall on the global poor (2020) (23)
- Evidence-informed evidence-making (2008) (23)
- Determining the value of drugs--the evolving British experience. (2011) (22)
- Implementing health technology assessment in Ghana to support universal health coverage: building relationships that focus on people, policy, and process (2019) (22)
- Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings (2018) (22)
- Adherence to the iDSI reference case among published cost-per-DALY averted studies (2018) (22)
- NCD Countdown 2030: efficient pathways and strategic investments to accelerate progress towards the Sustainable Development Goal target 3.4 in low-income and middle-income countries (2022) (22)
- Coverage with evidence development: A very good beginning, but much to be done. Commentary to Hutton et al. (2007) (21)
- The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review (2021) (21)
- Quality of Health Care in Ghana: Mapping of Interventions and the Way Forward. (2017) (21)
- Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis? (2019) (20)
- Health Technology Assessment: Global Advocacy and Local Realities (2016) (20)
- Public participation in decision-making on the coverage of new antivirals for hepatitis C. (2016) (18)
- Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers. (2009) (18)
- Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India (2018) (17)
- Eliminating waste in healthcare spending (2017) (17)
- The economic burden of cancer care for Syrian refugees: a population-based modelling study. (2020) (17)
- National Institute for Health and Care Excellence, social values and healthcare priority setting (2019) (17)
- Achieving high-quality universal health coverage: a perspective from the National Health Service in England (2018) (17)
- The cost-effectiveness of surgical instrument management policies to reduce the risk of vCJD transmission to humans (2009) (16)
- Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana (2020) (16)
- National Health Insurance in South Africa: Relevance of a national priority-setting agency. (2015) (16)
- Adaptive health technology assessment to facilitate priority setting in low- and middle-income countries (2021) (16)
- Prevention of non-communicable disease: best buys, wasted buys, and contestable buys (2020) (16)
- Using Comparative Effectiveness Research to Inform Policy and Practice in the UK NHS (2012) (16)
- Historical development of the htasialink network and its key determinants of success (2018) (15)
- Eliminating drug price differentials across government programmes in the USA (2010) (15)
- The opportunity cost of cancer care: a statement from NICE. (2011) (15)
- An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations (2021) (14)
- Ending AIDS as a public health threat by 2030: Time to reset targets for 2025 (2021) (14)
- COVID-19 Vaccine Predictions: Using Mathematical Modelling and Expert Opinions to Estimate Timelines and Probabilities of Success of COVID-19 Vaccines (2020) (13)
- Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India (2018) (13)
- Identification of publicly available data sources to inform the conduct of Health Technology Assessment in India. (2018) (13)
- On results reporting and evidentiary standards: spotlight on the Global Fund (2019) (13)
- Introducing health technology assessment in Tanzania (2019) (13)
- What are the best societal investments for improving people’s health? (2018) (12)
- Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays? (2018) (12)
- Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesis (2021) (11)
- A Health Economics Approach to US Value Frameworks: Serving the Needs of Decision Making. (2018) (10)
- Pharmacogenetics and cost-effectiveness analysis: a two-way street. (2011) (10)
- The (Possible) Impact of Comparative Effectiveness Research on Pharmaceutical Industry Decision Making (2010) (10)
- "You Travel Faster Alone, but Further Together": Learning From a Cross Country Research Collaboration From a British Council Newton Fund Grant (2018) (10)
- Distributional equity as a consideration in economic and modelling evaluations of health taxes: A systematic review. (2020) (9)
- Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence. (2012) (9)
- Value of Information Choices that Influence Estimates: A Systematic Review of Prevailing Considerations (2018) (8)
- Improving quality for maternal care - a case study from Kerala, India (2016) (8)
- Evidence for health policy (2006) (8)
- Mind the costs, too: towards better cost-effectiveness analyses of PBF programmes (2018) (8)
- The potential health and revenue effects of a tax on sugar sweetened beverages in Zambia (2020) (8)
- Improving Access to Innovative Medicines in Emerging Markets: Evidence and Diplomacy as Alternatives to the Unsustainable Status Quo (2013) (8)
- What do we need to know? Data sources to support evidence-based decisions using health technology assessment in Ghana (2020) (8)
- Radical changes in medical education needed globally. (2015) (8)
- Aggregating Demand for Pharmaceuticals is Appealing, but Pooling Is Not a Panacea (2019) (8)
- Should Countries Set an Explicit Health Benefits Package? The Case of the English National Health Service☆ (2017) (8)
- Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. (2019) (7)
- Cuban medical training for South African students: a mixed methods study (2019) (7)
- How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? (2021) (7)
- Ebola control: the Cuban approach (2014) (7)
- Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders. (2020) (6)
- Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making (2021) (6)
- Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem? (2021) (6)
- Leave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines (2020) (6)
- Economics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment (2020) (6)
- Combating antimicrobial resistance: quality standards for prescribing for respiratory infections in Vietnam. (2016) (5)
- Sharing the British National Health Service around the world: a self-interested perspective (2013) (5)
- How can we make better health decisions: a Best Buy for all? (2020) (5)
- Value-based tiered pricing for universal health coverage: an idea worth revisiting (2020) (5)
- Building Capacity for Evidence-Informed Priority Setting in the Indian Health System: An International Collaborative Experience☆ (2020) (5)
- Six Reasons Why the Global Fund Should Adopt Health Technology Assessment (2017) (5)
- Aff ordable cancer care 2 Evidence-informed frameworks for cost-eff ective cancer care and prevention in low , middle, and high-income countries (2014) (5)
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy (2022) (5)
- Imbalances in funding for clinical and public health research in the UK: can NICE research recommendations make a difference? (2008) (5)
- The Future of Global Health Procurement: Issues around Pricing Transparency (2019) (5)
- Piloting the development of a cost-effective evidence-informed clinical pathway: Managing hypertension in Jordanian primary care (2010) (5)
- Recalibrating the notion of modelling for policymaking during pandemics (2022) (5)
- Dialysis in Africa: the need for evidence-informed decision making (2020) (5)
- Disease Control Priorities Third Edition: Time to Put a Theory of Change Into Practice (2018) (5)
- Value-based tiered pricing for universal health coverage: an idea worth revisiting. (2020) (5)
- Comparative effectiveness research: a useful tool. (2009) (4)
- How can we make better health decisions a Best Buy for all?: Commentary based on discussions at iDSI roundtable on 2 nd May 2019 London, UK. (2019) (4)
- The NHS: assessing new technologies, NICE and value for money. (2011) (4)
- Key messages from Setting Priorities Fairly: Sustainable Policies for Effective Resource Allocation (2018) (4)
- Information will be the key to successful implementation (2015) (4)
- Medical training for universal health coverage: a review of Cuba–South Africa collaboration (2020) (4)
- Modicare Post-election : Recommendations to Enhance the Impact of Public Health Insurance on UHC Goals in India (2019) (4)
- Charging for the use of survey instruments on population health: the case of quality-adjusted life years (2019) (3)
- Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB (2020) (3)
- Making Choices on the Journey to Universal Health Care Coverage: From Advocacy to Analysis. (2016) (3)
- Clinical Pathways, Claims Data, And Measuring Quality. (2017) (3)
- Comparative effectiveness research around the globe: a valuable tool for achieving and sustaining universal healthcare. (2017) (3)
- Improving the quality and efficiency of healthcare services in Ghana through HTA (2017) (3)
- Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe". (2020) (3)
- Better outcomes through learning, data, engagement, and research (bolder) – a system for improving evidence and clinical practice in low and middle income countries (2016) (3)
- Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content. (2021) (3)
- High US Health-Care Spending and the Importance of Provider Payment Rates (2012) (3)
- The Value of Health Technology Assessment: a mixed methods framework (2017) (3)
- International Decision Support Initiative: Mapping of Priority-Setting in Health for 17 Low and Middle Countries Across Asia, Latin America and Africa (2015) (3)
- Do We Know Enough to End the Pandemic? (2020) (2)
- Fairer financing of vaccines in a world living with COVID-19 (2020) (2)
- The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy” (2015) (2)
- Capacity for health economics research and practice in Jordan, Lebanon, the occupied Palestinian territories and Turkey: needs assessment and options for development (2020) (2)
- Assessing evidence and prioritizing clinical and public health guidance recommendations: the NICE way (2009) (2)
- Assessing the performance of health technology assessment (HTA) agencies: developing a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact (2021) (2)
- iDSI HTA survey SSA Data sharing (2020) (2)
- Improving Quality and Efficiency in Health Care through Comparative Effectiveness Analyses : An International Perspective (2014) (2)
- Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries (2018) (2)
- What is the value of explicit priority setting for health interventions? A simulation study (2022) (2)
- USA stockpiling of remdesivir: How should the world respond? (2020) (2)
- From research to health care practice: how the UK uses data on comparative effectiveness. Interview by Bridget M. Kuehn. (2010) (2)
- Harnessing the power of health taxes (2020) (2)
- Developing and piloting a context-specified ethics framework for health technology assessment: the South African Values and Ethics for Universal Health Coverage approach (2022) (2)
- Health Technology Assessment capacity development in low-and middle-income countries: Experiences from the international units of HITAP and NICE [version 1; peer review: 2 approved] (2020) (1)
- The Global Fund impact – Authors' reply (2019) (1)
- How concentrated are academic publications of countries' progression towards universal health coverage? (2019) (1)
- The journey to UHC: how well are vertical programmes integrated in the health benefits package? A scoping review (2021) (1)
- Is competition bad for our health(care)? We simply don't know. (2017) (1)
- The International Decision Support Initiative (iDSI) Reference Case for Health Economic Evaluation (2019) (1)
- Process matters for priority setting and health technology assessment in Indonesia (2019) (1)
- What Counts in Economic Evaluations in Health? Benefit-cost Analysis Compared to Other Forms of Economic Evaluations (2020) (1)
- Improving the quality of economic evaluation in health in low- and middle-income countries: where are we now? (2019) (1)
- Using COVID-19 Test, Trace, and Isolate Systems Effectively in Middle-Income Countries (2020) (1)
- Value-based tiered pricing for universal health coverage: an idea worth revisiting. (2020) (1)
- The International Decision Support Initiative (iDSI) Health Technology Assessment capacity questionnaire (2018) (1)
- Considering equity in priority setting using transmission models: Recommendations and data needs (2022) (1)
- We need a NICE for global development spending (2017) (1)
- Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders [version 1; peer review: 2 approved] (2021) (1)
- Introducing an Ethics Framework for health priority-setting in South Africa on the path to universal health coverage. (2022) (1)
- 9. Deliberative Processes in Decisions about Best Buys, Wasted Buys, and Contestable Buys (2019) (1)
- Policy Considerations: Ex-US Payers and Regulators (2017) (1)
- Valuing Protection against Health-Related Financial Risks (2019) (1)
- 研究会Review(No.463)NICEの現状と今後について (2007) (0)
- Setting fundable priorities for universal healthcare coverage: global concept, local applications (2017) (0)
- Healthcare Systems as Intelligent Payers : What Can the Global Health Community Learn from the English National Health Service ? (2018) (0)
- Redesigning Health Care in ECA: Some Lessons from the UK (2010) (0)
- National Health Insurance in South Africa : relevance of a national priority-setting agency : editorial (2015) (0)
- Spending on Medical Care (2017) (0)
- The international Decision Support Initiative (iDSI): presentation to BMGF India Country Office Brown Bag event October 2017 (2018) (0)
- PIH38 EVALUATING THE HEALTH TECHNOLOGY ASSESSMENT PROGRAM IN THAILAND (2010) (0)
- iDSI: support for priority setting in India (2018) (0)
- The role of Tip60 and acetylation in prostate cancer. (2003) (0)
- Assessing the Added Value of Health Technologies: NICE’s Experience in England (2009) (0)
- S15– Adapting NICE guidance for a developing country (2010) (0)
- Redesigning health care in Europe and Central Asia (ECA) : some lessons from the UK (2010) (0)
- The Challenges of Developing Cost-Effective Public Health Guidance: A NICE Perspective (2009) (0)
- Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders (2021) (0)
- Interview: Setting up NICE International. (2012) (0)
- 180:oral Designing health benefit packages for universal health coverage – should countries follow a sectoral, incremental or hybrid approach? (2022) (0)
- Correction to: Recommendations from Two Citizens’ Juries on the Surgical Management of Obesity (2018) (0)
- Equity as a consideration in evaluations of health taxes: a systematic review (2019) (0)
- Medical Decision Making and MDM Policy & Practice Reviewers, 2016 (2017) (0)
- Why Uncertainty in Global Health Interventions Matters — and What We Can Do About It (2019) (0)
- The Current Status of Priority-setting and Health Technology Assessment for Universal Health Coverage in India (2019) (0)
- Audit of submissions: July 2016-June 2017. (2018) (0)
- Building Institutions for Priority-Setting (2019) (0)
- PIN90 HEALTH-ECONOMIC MODELLING TO INFORM PRIVATE SECTOR INVESTMENT IN INFECTIOUS DISEASE TREATMENTS IN MIDDLE-INCOME COUNTRIES: THE CASE OF TUBERCULOSIS (2019) (0)
- Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook" (2021) (0)
- Cuban medical training for South African students: a mixed methods study (2019) (0)
- Kalipso Chalkidou: Internationally NICE (2016) (0)
- THE COMMONWEALTH FUND 2007-08 HARKNESS FELLOWSHIPS IN HEALTH CARE POLICY AND PRACTICE ORIENTATION SEMINAR PARTICIPANT CONTACT LIST (2007) (0)
- Organising Research and Development for evidence-informed health care: some universal characteristics and a case study from the UK (2021) (0)
- S0266462319000588jra 80..86 (2020) (0)
- Reforming the NHS (2011) (0)
- A new initiative to track HIV resource allocation and costs (2022) (0)
- ROAD2H: Learning Decision Support System for Low- and Middle-Income Countries (2019) (0)
This paper list is powered by the following services:
Other Resources About Kalipso Chalkidou
What Schools Are Affiliated With Kalipso Chalkidou?
Kalipso Chalkidou is affiliated with the following schools:
